This invention entails continuous flow reactor technology that is used to manufacture active pharmaceutical ingredients (APIs) for various drugs. These include AIDS (i.e. Emtricitabine, Lamivudine and Efavirenz), TB (Isoniazid), influenza (Tamiflu) and diabetes (Gliclazide, chlorpropamide, glipizide, glibenclamide and tolbutamide). The project outcomes demonstrated that these can be manufactured cost-effectively using the continuous flow method compared to when they are produced using the conventional batch manufacturing process.
The invention addresses the urgent need for a cost-effective method to produce APIs compared to the prices the pharmaceutical industry charges from importing. Hospitals, clinics, and private practices will make use of these cost-effective drugs taking the middleman away for these specific drugs.
Medicine is inaccessible to most patients due to the expensive and inadequate supply of APIs. This new technology, namely continuous flow reactors, will develop cost-effective routes to manufacture a variety of key drugs.
TRL6
Yes
IP TYPE
Patents
INVENTOR
Prof Paul Watts
Funding | Investment